NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) released its quarterly earnings data on Thursday, February, 6th. The medical equipment provider reported $1.51 EPS for the quarter, topping analysts' consensus estimates of $1.09 by $0.42. The medical equipment provider had revenue of $221.60 million for the quarter, compared to the consensus estimate of $226.92 million. ABIOMED had a return on equity of 19.53% and a net margin of 29.14%. The company's quarterly revenue was up 10.5% compared to the same quarter last year. During the same period last year, the business posted $0.97 EPS. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for ABIOMED.

ABIOMED issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $846-877 million, compared to the consensus revenue estimate of $885.43 million.

7 brokers have issued twelve-month price objectives for ABIOMED's stock. Their forecasts range from $165.00 to $340.00. On average, they expect ABIOMED's stock price to reach $248.33 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price. View Analyst Price Targets for ABIOMED.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED.

Media headlines about ABMD stock have been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ABIOMED earned a news impact score of -1.0 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for ABIOMED.

ABIOMED saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 4,250,000 shares, an increase of 5.7% from the January 30th total of 4,020,000 shares. Based on an average daily volume of 884,300 shares, the short-interest ratio is presently 4.8 days. Approximately 9.7% of the company's stock are sold short. View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Arista Networks (ANET), Align Technology (ALGN), Netflix (NFLX), Square (SQ), bluebird bio (BLUE), Paypal (PYPL) and salesforce.com (CRM).

ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (6.04%), Sands Capital Management LLC (5.42%), Renaissance Technologies LLC (5.16%), State Street Corp (4.56%), Alliancebernstein L.P. (2.11%) and Geode Capital Management LLC (1.58%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Amundi Pioneer Asset Management Inc., Victory Capital Management Inc., Victory Capital Management Inc., Standard Life Aberdeen plc, Baird Financial Group Inc., Villere ST Denis J & Co. LLC and William Blair Investment Management LLC. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Alliancebernstein L.P., Credit Suisse AG, Jackson Square Partners LLC, Renaissance Technologies LLC, Bessemer Group Inc., Global Thematic Partners LLC and State Street Corp. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $153.91.

ABIOMED has a market capitalization of $6.94 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED.

The official website for ABIOMED is http://www.abiomed.com/.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]